UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 7, 2019

KEZAR LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Registrant's telephone number, including area code:  (650) 822-5600

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

Item 2.02. Results of Operations and Financial Condition.

Preliminary Estimate of Selected Fiscal Year End 2018 Financial Results

Kezar Life Sciences, Inc. (“Kezar”) preliminarily estimates that its cash, cash equivalents and marketable securities as of December 31, 2018 was approximately $107.4 million and that it had 19.1 million shares of common stock outstanding as of December 31, 2018. These preliminary estimates are not a comprehensive statement of Kezar’s financial results for the year ended December 31, 2018 and have not been audited, reviewed, or compiled by its independent registered public accounting firm. Kezar’s actual consolidated cash, cash equivalents and marketable securities balance and shares of common stock outstanding as of December 31, 2018 may differ from these estimates due to the completion of Kezar’s year-end closing and auditing procedures.

The information provided in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:  January 7, 2019